Until now, treatments could only ease symptoms a little. But this new medication (donanemab, administered by infusion every four weeks) goes much further: it's an antibody that destroys the toxic plaques that accumulate in the brain and damage neurons. On average, the treatment manages to slow the progression of the disease and cognitive decline by a third. It's precious extra time and improved quality of life for patients.
The crucial importance of early detection
One caveat though: this treatment is only suitable for people diagnosed at a very early stage (roughly 7 to 15% of patients). Which is why it's so important to speak up at the slightest concern and to rely on preventive memory tests developed in Geneva. Even though it requires very strict medical monitoring, it's a huge step forward that proves research is finally making real progress!
The Hospices Civils de Lyon (notably Pierre Wertheimer Hospital) were among the centers that participated in the global phase 3 clinical trials of this molecule. Although the European Commission granted market authorization for Kisunla in September 2025, the High Health Authority (HAS) in France issued in March 2026 a More info